Table 1.
Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Nucleocapsid Serology in 22 Participants
| Participant ID | Clinical Diagnosis | Roche Elecsys | MSD ECLA | Simoa |
|---|---|---|---|---|
| 1 | + | + | + | + |
| 2 | + | + | + | + |
| 3 | + | + | + | + |
| 4 | + | + | + | + |
| 5 | + | + | + | + |
| 6 | + | + | + | + |
| 7 | + | + | + | + |
| 8 | + | + | + | + |
| 9 | + | + | + | + |
| 10 | – | + | + | + |
| 11 | – | – | + | + |
| 12 | – | – | + | + |
| 13 | – | – | + | + |
| 14 | – | – | + | + |
| 15 | – | – | – | + |
| 16 | – | – | – | + |
| 17 | – | – | – | + |
| 18 | – | – | – | + |
| 19 | – | – | – | + |
| 20 | – | – | – | + |
| 21 | – | – | – | + |
| 22 | – | – | – | – |
Table shows clinically diagnosed severe acute respiratory syndrome coronavirus 2 infection by reverse-transcription polymerase chain reaction and nucleocapsid serology by the approved Roche Elecsys immunoassay, the Mesoscale Discovery (MSD) electrochemiluminescence assay (ECLA), and the single-molecule array assay (Simoa).